Oral Treatment with Live Lactobacillus reuteri Inhibits the Allergic Airway Response in Mice

• DOI: 10.1164/rccm.200606-821oc
• Publication Date: 2007-01-05T02:00:01Z
• Authors: Paul Forsythe; Mark D. Inman; John Bienenstock
• Keywords: Lactobacillus reuteri; Lactobacillus salivarius

Clinical trials have demonstrated that probiotics may be effective in the treatment and prevention of atopic disease children but there been few reports therapeutic effects oral outside gastrointestinal tract.We investigated effect two probiotic organisms on response to antigen challenge a mouse model allergic airway inflammation.We used an ovalbumin-sensitized asthma BALB/c Toll-like receptor 9-deficient mice. Animals were treated with via gavaging needle before challenge. After challenge, responsiveness methacholine, influx inflammatory cells lung, cytokine levels bronchoalveolar lavage fluid assessed.Oral live Lactobacillus reuteri not salivarius significantly attenuated eosinophils lumen parenchyma reduced tumor necrosis factor, monocyte chemoattractant protein-1, IL-5, IL-13 antigen-challenged animals, was no change eotaxin or IL-10. L. also decreased allergen-induced hyperresponsiveness. These responses dependent 9 associated increased activity indoleamine 2,3-dioxygenase. Killed did mimic ability attenuate inflammation hyperresponsiveness.Oral can major characteristics asthmatic inflammation. results suggest specific strains potential disease.